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Describing the effects of treatment
The effects of treatment are conventionally expressed in relative terms-the ratio of the event rate in the treatment group divided by the event rate in the control group. Ratios greater than one imply that treatment is harmful, less than one, that treatment is beneficial. This hides the fact that a small relative benefit applied to patients at very high risk will generate more lives saved (and non-fatal events avoided) than the same relative benefit applied to much lower risk patients. However, the relative treatment effect may be dependent on the baseline level of risk in the control group. For example, surgery for carotid endarterectomy is effective for high risk tight stenosis but not for low risk smaller degrees of stenosis. 3 It cannot be assumed that treat- ment effects are constant across a wide range of baseline levels of risk. The absolute effects of treatment take account of baseline level of risk and are simply the difference between intervention and control group rates. From a clinical and public health standpoint it is useful to have some idea of the amount of effort required to avoid one adverse event. This is given by the reciprocal of the absolute risk difference-the number needed to treat. 4 The absolute effect and the NNT will vary-often greatly-according to the baseline level of risk and this means that a single measure of effect applicable to different age groups, for example, cannot be derived.
Baseline levels of risk vary
So far so simple, but the NNT has some rather disturbing characteristics that make it difficult to use in practice. Which baseline level of risk should be used? In the trials of antihypertensives among older patients without previous cardiovascular disease, [5] [6] [7] [8] [9] [10] [11] baseline risk varied widely (see Table 1 ). For total, coronary heart disease (CHD) and stroke mortality control group rates varied by 5.3, 3.5 and 12-fold respectively. These differences are not due to the play of chance but are produced by the design characteristics of the trials themselves-the clinical setting, level of blood pressure, comorbidity, age and sex of the participants.
The effect of choice of outcome on NNT
As demonstrated in Table 1 , not only do baseline levels of risk vary, but so do NNTs, depending on the outcomes considered. If the most common outcome is used (eg, all bad things that can happen to you, or a combined cardiovascular end-point) then the NNT is lower than if an uncommon, but poten- tially more important outcome is used (eg, mortality). Choice of outcome for NNT calculations can make or break the case for using a specific treatment, as can choice of trial to derive baseline risks. NNTs can be easily inflated or deflated by the duration of treatment considered. A single year NNT is five times larger than a 5-year NNT. In mild hypertension, this is the difference between NNTs to prevent one stroke of 833 and 167! And if the overall cardiovascular event rate is used as the outcome, rather than stroke, the 1-year and 5-year NNTs fall to 667 and 133.
Ineffective treatments
A mathematical quirk of the NNT is that if the treatment has no effect, that is the event rates are identical in both the treatment and control groups, then the absolute risk difference is zero, and 1/zero, the NNT, is infinity. 12 This is demonstrated by the Sprackling trial in Table 1 which had identical death rates in intervention and control groups. 6 Thus, a treatment of little effect will have a lower confidence interval of the absolute risk difference that is negative and an upper confidence interval that is positive. If the treatment produces an adverse effect then a number needed to harm, rather than a NNT, is the outcome. If confidence intervals of treatment efficacy overlap a null effect, then the confidence intervals of the NNT will stretch from a negative value (ie, number needed to harm) at the lower border, include infinity, and stretch to a NNT at the upper border. It is rather confusing to have a measure of effect with confidence intervals that may include benefit, harm and infinity! (See Figure 1) .
Trial participants and patients in routine clinical practice
Patients entered into randomised controlled trials are a selected group. In most randomised controlled trials, participants are at lower risk than might be expected because with given eligibility criteria healthier people are more likely to end up enrolled in trials. Thus trial baseline risks may be quite inappropriate to apply in clinical practice. This will tend to inflate the apparent NNT. In the MRC mild hyper- Figure 1 Relationship between absolute risk difference and numbers needed to treat. When the risk difference is zero, number needed to treat is ϱ. tension trial event rates were much lower than in epidemiological studies and for fatal events were closer to those expected for normotensive men rather than hypertensive men. These differences reflect the selection bias mentioned above, and raise serious questions about the value of trial-derived NNTs (see Table 2 ). Selection bias may work in the opposite direction occasionally. In the Hypertension Detection and Follow Up Program-a comparison of careful stepped care versus usual care-baseline risks of death were very high because the participants were predominately poor, and many were black. 13 Clinicians who want to use NNTs have to make a judgment about which baseline risk applies to their patients and without local epidemiological data this is difficult.
Geographical and secular trends and their effects on NNT
Further concerns in using NNTs are that geographic and secular trends in the baseline risk of cardiovascular diseases can be marked. For example, ischaemic heart disease and stroke mortality rates are about twice as high in the north as the south of a Number needed to harm as event rates were higher in treated group than placebo for coronary deaths.
the Britain.
14 Consequently, the relevant cardiovascular disease (CVD) baseline risk for a Scottish GP will be twice that of a home counties GP, resulting in an NNT for antihypertensive treatment that is twice as great in the south of England as in Scotland. Similarly, CVD variation between countries results in NNTs that differ in direct proportion to the underlying event rates.
Secular trends in stroke produce the same sort of effect. Stroke mortality rates are falling dramatically in most Western countries 15 and with this fall, NNTs for antihypertensive treatment will also fall over time. Table 3 shows the effects that may be expected on NNTs, assuming baseline event rates in hypertensives are twice those in the general population and that the relative risk reduction for stroke mortality on antihypertensive treatment is 33%. It is clear that NNTs vary widely over time, are higher in women than men-reflecting women's lower baseline riskand are considerably lower than NNTs derived from participants in randomised controlled trials.
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Meta-analysis and NNTs
There is an increasing trend for meta-analyses of treatments to provide pooled estimates of NNTs in addition to conventional relative risk estimates of effects. 16 Available software, including the Cochrane Library Meta-View package permit absolute risk differences, and hence NNTs, to be calculated easily. Such pooled NNTs are potentially misleading as they encourage assumptions that clinical patient risk is similar to trial patient risk. They may fail to allow for different lengths of follow-up in trials, they contravene statistical assumptions in pooling of data, and hide the heterogeneity of NNTs due to trial inclusion criteria which is of use to the clinician in making treatment decisions. 17 In summary, NNTs may be useful to illustrate the range of workload that is required to achieve benefits from treatments in a rough and ready way. NNTs are less useful than is often supposed in communicating effects of individual treatment decisions since they vary between patient groups, clinical settings, places and over time, in ways which clinicians will usually not have adequate data to take into account.
